Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.

2.50
Hdl Handle:
http://hdl.handle.net/10541/100237
Title:
Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.
Authors:
Stewart, James P; McGown, Alan T; Prendiville, Joseph A; Pettit, G R; Fox, Brian W; Arrand, John R
Abstract:
Bryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.
Affiliation:
CRC Department of Molecular Biology, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.
Citation:
Bryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients. 1993, 33 (1):89-91 Cancer Chemother. Pharmacol.
Journal:
Cancer Chemotherapy and Pharmacology
Issue Date:
1993
URI:
http://hdl.handle.net/10541/100237
DOI:
10.1007/BF00686030
PubMed ID:
8269596
Type:
Article
Language:
en
ISSN:
0344-5704
Appears in Collections:
All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorStewart, James Pen
dc.contributor.authorMcGown, Alan Ten
dc.contributor.authorPrendiville, Joseph Aen
dc.contributor.authorPettit, G Ren
dc.contributor.authorFox, Brian Wen
dc.contributor.authorArrand, John Ren
dc.date.accessioned2010-06-03T15:17:38Z-
dc.date.available2010-06-03T15:17:38Z-
dc.date.issued1993-
dc.identifier.citationBryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients. 1993, 33 (1):89-91 Cancer Chemother. Pharmacol.en
dc.identifier.issn0344-5704-
dc.identifier.pmid8269596-
dc.identifier.doi10.1007/BF00686030-
dc.identifier.urihttp://hdl.handle.net/10541/100237-
dc.description.abstractBryostatin 1 is a novel anti-tumor agent currently undergoing clinical trial. We investigated the effect of this drug on B-lymphocyte cell lines that carry the Epstein-Barr virus and found that it induces these latently infected cells into the production of transforming virus particles over a wide range of concentrations. These results may have clinical implications, particularly with regard to the use of the drug in the immunocompromised patient.en
dc.language.isoenen
dc.subject.meshAntineoplastic Agents-
dc.subject.meshB-Lymphocytes-
dc.subject.meshBryostatins-
dc.subject.meshCell Transformation, Viral-
dc.subject.meshHerpesvirus 4, Human-
dc.subject.meshHumans-
dc.subject.meshImmunocompromised Host-
dc.subject.meshLactones-
dc.subject.meshMacrolides-
dc.subject.meshTetradecanoylphorbol Acetate-
dc.subject.meshVirus Latency-
dc.subject.meshVirus Replication-
dc.titleBryostatin 1 induces productive Epstein-Barr virus replication in latently infected cells: implications for use in immunocompromised patients.en
dc.typeArticleen
dc.contributor.departmentCRC Department of Molecular Biology, Paterson Institute for Cancer Research, Christie CRC Cancer Centre, Manchester, UK.en
dc.identifier.journalCancer Chemotherapy and Pharmacologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.